Although novel agents effective against malignant mesothelioma (MM) have been developed, the prognosis of patients with MM is still poor. We generated a DNA-chimeric siRNA against polo-like kinase-1 (PLK-1), which was more stable in human serum than the non-chimeric siRNA. The chimeric PLK-1 siRNA inhibited MM cell proliferation through the induction of apoptosis. Next, we investigated the effects of zoledronic acid (ZOL) on MM cells, and found that ZOL also induced apoptosis in MM cells. Furthermore, ZOL augmented the inhibitory effects of the PLK-1 siRNA. In conclusion, combining a PLK-1 siRNA with ZOL treatment is an attractive strategy against MM.
Introduction
Malignant mesothelioma (MM) is an aggressive tumor, which develops from the mesothelial surface of the pleural and peritoneal cavities. Asbestos is well-known as a carcinogen in MM and the incidence of MM is increasing worldwide [1] .
Although several surgical approaches have been proven to be effective [2, 3] , a combination of therapies including chemotherapeutic agents, radiation, and immunotherapy are required to fight the disease. However, in spite of the emergence of novel effective anticancer agents such as pemetrexed [4, 5] and raltitrexed [6, 7] , the prognosis of patients with MM is still poor [8, 9] . Therefore, the development of novel effective therapeutic strategies is essential to improve the prognosis of this disease.
RNA interference (RNAi) is a process involving sequence specific post-transcriptional gene silencing induced by double-stranded (ds) RNA. It is widely applied as a powerful tool in postgenomic research, and has been experimentally introduced into the field of cancer therapy. Synthetic, short interfering RNAs (siRNAs) for inducing RNAi are 19-to 21-nucleotide dsRNAs with two-nucleotide 3' overhangs at either end [10, 11] . Unfotunately, siRNAs are degraded by endogenous nucleases when administered in vivo. Many techniques, including the use of DNA-chimeric siRNAs, have been developed to protect siRNAs from such degradation [10,12,13]. Previous investigations have revealed that their silencing activity is as powerful as that of non-chimeric siRNAs [12] [13] [14] .
Polo-like kinase-1 (PLK-1) belongs to the PLK family of serine/threonine kinases and is highly conserved among eukaryotes. PLK-1 regulates cell division at several points during the mitotic phase of the cell cycle, including: mitotic entry through CDK1 activation, bipolar spindle formation, chromosome alignment, segregation of chromosomes, and cytokinesis [15, 16] . Previous studies have reported that PLK-1 is overexpressed in cancerous tissues and that PLK-1 expression levels are tightly correlated with histological grades of tumors, clinical stages, and the patients' prognosis [17] [18] [19] [20] . Thus, PLK-1 is considered to be a suitable target for cancer therapy, and several small molecular targeting agents have been used in clinical trials [21, 22] , while siRNAs against PLK-1 have been investigated in preclinical studies [19, 20, 23] .
Bisphosphonates (BPs) are inhibitors of bone-resorption, and second-and third-generation BPs have been developed primarily to treat benign and malignant bone disease [24] . This class of drugs inhibits the proliferation of cancer cells by preventing the post-translational prenylation of small GTPases including the Ras family proteins [25] . We have demonstrated previously that third-generation BPs such as zoledronic acid (ZOL) and minodronic acid (YM529) have direct anti-tumor effects In the present study, we have investigated the effects of a DNA-chimeric PLK-1 siRNA and ZOL on MM cells in vitro. Our results show that these agents induce apoptosis and inhibit the proliferation of MM cells. In addition, we found that ZOL enhances the inhibitory effects of the PLK-1 siRNA.
Materials and Methods

Cell lines, reagents, and animals
The human MM cell lines H2452, H2052, H28, and 211H were cultured in RPMI1640 medium (Gibco, Tokyo, Japan) containing 10% heat-inactivated fetal calf serum (FCS; Invitrogen, Tokyo, Japan), l-glutamine (Gibco), and 1% penicillin-streptomycin (Gibco). The normal human dermal fibroblast (NHDF) cells were cultured in Dulbecco's Modified Eagle medium (DMEM; Gibco) containing 10% FCS, l-glutamine, and 1% penicillin-streptomycin. All cell lines were maintained at 37°C in a fully humidified atmosphere of 5% CO 2 in air. All four MM cell lines were obtained from the American Type Culture Collection (Rockville, MD). Normal fibroblast NHDF cells were purchased from Kurabo (Osaka, Japan). LIC™ Transfection Reagent (Hayashi Kasei, Tokyo, Japan) was used for transfection into We generated two types of siRNA against PLK-1 (GenBank accession number NM_005030) using siDIRECT™ (alphaGEN Co, Ltd, Tokyo, Japan). One of the siRNAs contained of ribonucleotides and the other was a DNA-chimeric siRNA consisting partially of deoxyribonucleotides. The oligonucleotide sequences of the non-chimeric PLK-1 siRNA against PLK-1 were: sense strands, 5'-
GCACCGAAACCGAGUUAUUCA-3'
and that antisense strand, 5′-AAUAACUCGGUUUCGGUGCAG-3′. The sequences of the DNA-chimeric siRNA against PLK-1 were: sense strand, 5'-GCACCGAAACCGAgttattca-3', and antisense strand, 5'-aataacUCGGUUUCGGUGCAG-3'. This DNA-modified siRNA was constructed by substituting six ribonucleotides at the 5' end of the guide strand and the 3' end of the passenger strand with the cognate deoxyribonucleotides (designated in lower case). The oligonucleotide sequences for the chimeric siRNA controls were: sense strand, 5'-GUACCGCACGUCAttcgtatt-3', and antisense strand, 5'-tacgaaUGACGUGCGGUACGU-3'. The sequences for the non-chimeric control siRNA were: sense strand, 5'-GUACCGCACGUCAUUCGUAUU-3', and antisense strand, 5'-UACGAAUGACGUGCGGUACGU-3'. All siRNAs used were chemically synthesized (Hokkaido System Science Co. Ltd, Hokkaido, Japan).
Stability of the DNA-chimera siRNA in human serum
We investigated the stability of the DNA-chimeric and non-chimeric siRNAs in human serum. Each siRNA was incubated in human serum (95%) at 37°C. Serum RNase was inactivated by adding SDS and proteinase K, and then digested samples were loaded onto 15% polyacrylamide gel, which was then stained using SYBR Gold (Invitrogen).
Growth inhibitory effects of PLK-1 siRNA
Cell proliferation was determined by the modified MTT assay using the Cell- which has been widely used to evaluate interactions of antineoplastic agents [33] [34] [35] [36] .
Cells were incubated for 72 hours with six concentrations (0.25, 0.5, 0.75, 1.0, 1.5, or 2.0 times the IC 50 ) of each agent or both in combination using the constant ratio design followed by the modified MTT assay. We calculated the combination indexes (CIs) as reported previously [33] [34] [35] [36] , and calculated the fraction affected (Fa) at each dilution (for example, Fa of 0.25 equals 75% viable cells). This method provides a quantification of the synergism (CI < 1), additive effect (CI = 1), and antagonism (CI > 
Cell cycle and apoptosis analysis
Cell cycle analysis using propidium iodide (PI) was performed as previously 
Western blotting analysis
Following the transfection of cells with PLK-1 siRNA, or treatment with ZOL, as described above, the medium was aspirated and the cells were washed with ice-cold PBS (-). The cells were lysed with ice-cold RIPA buffer (50 mM Tris-HCl [pH 7.4], 0.25 M NaCl, 5 mM EDTA, 20 mM NaF, 1% NP-40) with PMSF (1 mM) and protease inhibitor (10 μg/ml). The cells were then scraped off the plate, and the suspension of cells in lysis buffer was transferred to a centrifuge tube, which was placed on ice for 15 
Results
Stability of the DNA-chimera siRNA in human serum
An siRNA can be protected from RNase or nuclease cleavage by the partial substitution of ribonucleotides with deoxyribonucleotides at the 5' end of the guide strand and the 3' end of the passenger strand. Therefore, we first designed the PLK-1 siRNA using siDIRECT™ and then converted this siRNA into a DNA-chimeric siRNA.
We incubated the DNA-chimeric, or non-chimeric siRNAs against PLK-1 in 95% human serum and investigated their degeneration. The non-chimeric siRNA degenerated in a time-dependent manner, while the DNA-chimeric siRNA did not degenerate for at least 120 minutes ( Fig. 1A ). This result shows that the chimeric siRNA is more stable in human serum than the non-chimeric siRNA.
DNA-chimeric PLK-1 siRNA inhibited the growth of mesothelioma cells
We examined the PLK-1 expression in four MM cell lines: H2452, H2042, H28, and 211H cell lines. All cell lines examined expressed a higher level of PLK-1 than normal NHDF fibroblast cells ( Fig. 1B ). Next we confirmed the knockdown effects of both DNA-chimeric and non-chimeric PLK-1 siRNAs in MM cells. We transfected both types of siRNAs into H2452 MM cells, and both siRNAs effectively knocked down PLK-1 expression ( Fig. 1C ). Then we investigated the inhibitory effects of the DNA-chimeric PLK-1 siRNA on MM cells in vitro. Western blot analysis showed that the transfection of the DNA-chimeric PLK-1 siRNA suppressed PLK-1 expression in H2452 mesothelioma cells in a dose-dependent manner, whereas the nonsense chimeric siRNA (100 nM) did not ( Fig. 2A ). The IC 50 values for H2452 and H28 cells at 72 hours exposure were 1.6 nM and 38.7 nM, respectively. Out next step was to examine the growth inhibitory effects of the DNA-chimeric siRNA against PLK-1 on H2452 and H28 mesothelioma cells using a modified MTT assay. As shown in Fig. 2B , the chimeric PLK-1 siRNA inhibited cell growth in a dose-dependent manner, whereas no significant inhibitory effects were detected in normal NHDF cells ( Fig. 2C ). 
The mechanisms of cell death induced by PLK-1 depletion
ZOL inhibits the growth of mesothelioma cells and synergistically augments with the effects of the PLK-1 siRNA
We examined the inhibitory effects of ZOL on H2452 and H28 mesothelioma cells using a modified MTT assay. ZOL inhibited cell growth in a dose-dependent manner, and the IC 50 values for H2452 and H28 cells at 72 hours exposures were 11.4
μM and 58.1 μM, respectively ( Fig. 4A) . ZOL treatment increased the subG1 fractions ( Fig. 4B ) and the number of apoptotic cells (Fig. 4C ) in a dose-dependent manner.
Furthermore, we found that caspase-3 was cleaved by ZOL treatment (Fig. 5A ).
Next we investigated the unprenylation of Rap1A, RhoA, and Ras proteins.
MM cell lysates were analyzed by Western blotting using Abs against Ras and the unprenylated form of Rap1A and RhoA. ZOL treatment resulted in an increase in unprenylated Rap1A and RhoA in MM cells (Fig. 5B ). The anti-Ras Ab recognizes both a slower migrating band, representing the unprenylated Ras, and a faster migrating band representing the prenylated Ras [37] . After ZOL treatment, there was an increase in the unprenylated form of Ras in MM cells which was accompanied by a reduction in the prenylated form ( Fig. 5B ). Taken together, the results indicate that 2'-O-methoxyethylation, and 2'-fluoro-2'-deoxynucleoside modification can improve nuclease resistance [41, 42] . Another approach involves the replacement of certain siRNA ribonucleotides with their deoxyribonucleotide counterparts.
We generated a DNA-chimeric siRNA, and substituted six basepairs from the 
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